Solid Biosciences $90 million common stock PIPE offering
Davis Polk advised the placement agent in connection with a private placement pursuant to Rule 4(a)(2) by Solid Biosciences Inc. of $90 million of common stock.
Solid Biosciences Inc…
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
ANA HOLDINGS ¥305.2 billion global stock offering
Davis Polk advised the joint global coordinators in connection with the global offering of 140,000,000 shares of common stock of ANA HOLDINGS INC., which included over-allotment…
Fiserv $2.2 billion secondary offering
Davis Polk advised the representatives of the several underwriters in connection with the $2.2 billion secondary offering of 20,125,000 shares of common stock of Fiserv, Inc. by New…
Freeport-McMoRan $550 million sale of mining interests to China Molybdenum
Davis Polk advised Freeport-McMoRan Inc. in connection with its $550 million sale of its interests in the Kisanfu project to a wholly owned subsidiary of China Molybdenum Co., Ltd. The…
Hydrofarm Holdings Group $199 million IPO
Davis Polk advised the representatives of the underwriters in connection with the $199 million initial public offering of 9,966,667 shares of common stock of Hydrofarm Holdings…
IHS Markit investment in Gen II Fund Services
Davis Polk advised IHS Markit in connection with its investment in Gen II Fund Services, LLC. The strategic investment was led by General Atlantic, a leading global growth equity firm, and…
MicroStrategy $650 million convertible senior notes offering
Davis Polk advised the initial purchaser in connection with a Rule 144A offering by MicroStrategy Incorporated of $650 million aggregate principal amount of its 0.750% convertible…
Murphy USA $645 million acquisition of QuickChek
Davis Polk is advising Murphy USA on its $645 million acquisition of QuickChek Corporation. The transaction is expected to close during the first quarter of 2021, subject to customary…
Open Lending $305.9 million secondary offering
Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the $305.9 million secondary offering of 10,925,000 shares of common stock…
Atara Biotherapeutics $175 million common stock and pre-funded warrants offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $175 million SEC-registered common stock and pre-funded warrants…